Coherus BioSciences, Inc. (CHRS) |
|
6 0 (0%)
|
03-27 16:00 |
|
Open: |
6.05 |
Pre. Close: |
6 |
|
High:
|
6.175 |
Low:
|
5.965 |
|
Volume:
|
728,754 |
Market Cap:
|
478(M) |
|
|
|
Technical analysis |
as of: 2023-03-27 4:18:10 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 8.11 One year: 9.01 |
| Support: |
Support1: 5.71 Support2: 4.75 |
| Resistance: |
Resistance1: 6.94 Resistance2: 7.71 |
| Pivot: |
6.28 |
| Moving Average: |
MA(5): 5.97 MA(20): 6.41
MA(100): 7.56 MA(250): 8.59 |
| MACD: |
MACD(12,26): -0.5  Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 15.2 %D(3): 14.4 |
| RSI: |
RSI(14): 36.9 |
| 52-week: |
High: 14.1 Low: 5.58 |
| Average Vol(K): |
3-Month: 1,166 (K) 10-Days: 1,118 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CHRS ] has closed above bottom band by 30.9%. Bollinger Bands are 32.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.08 - 6.1 |
6.1 - 6.13 |
|
Low:
|
5.75 - 5.77 |
5.77 - 5.8 |
|
Close:
|
5.95 - 5.99 |
5.99 - 6.04 |
|
Company Description |
|
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. |
Headline News |
Mon, 13 Mar 2023
Jacobs Levy Equity Management Inc. Sells 316737 Shares of ... - MarketBeat
Sun, 12 Mar 2023
Hsbc Holdings PLC Decreases Holdings in Coherus BioSciences ... - MarketBeat
Wed, 08 Mar 2023
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2022 Earnings Call Transcript - Yahoo Finance
Mon, 06 Mar 2023
After-Hours Earnings Report for March 6, 2023 : TCOM, NTNX ... - Nasdaq
Mon, 06 Mar 2023
FDA Approves UDENYCA® Autoinjector - GlobeNewswire
Mon, 06 Mar 2023
Coherus BioSciences: Q4 Earnings Snapshot - The Associated Press
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
80 (M) |
| Shares Float |
71 (M) |
|
% Held by Insiders
|
2 (%) |
|
% Held by Institutions
|
105 (%) |
|
Shares Short
|
9,840 (K) |
|
Shares Short P.Month
|
9,540 (K) |
Stock Financials |
|
EPS
|
-3 |
|
EPS Est Next Qtl
|
-0.76 |
|
EPS Est This Year
|
-5.14 |
|
EPS Est Next Year
|
-2.62 |
|
Book Value (p.s.)
|
-1.75 |
|
Profit Margin (%)
|
-138.3 |
|
Operating Margin (%)
|
-121.8 |
|
Return on Assets (ttm)
|
-27.7 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
-38.3 |
|
Gross Profit (p.s.)
|
-0.74 |
|
Sales Per Share
|
2.65 |
|
EBITDA (p.s.)
|
-3.19 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-241 (M) |
|
Levered Free Cash Flow
|
-191 (M) |
Stock Valuations |
|
PE Ratio
|
-2.01 |
|
PEG Ratio
|
0.1 |
|
Price to Book value
|
-3.45 |
|
Price to Sales
|
2.26 |
|
Price to Cash Flow
|
-1.99 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
